Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01120379 · ClinicalTrials.gov registry record

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)

A clinical trial of Coronary Artery Disease and Coronary Disease, sponsored by Abbott Medical Devices.

Completed
Registry status
5,034
Enrollment target
1
Study location

NCT01120379 is a study of Coronary Artery Disease and Coronary Disease that has completed, run by Abbott Medical Devices. The registered enrollment target is 5,034 participants, above the 1,264-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (298% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01120379, a study of Coronary Artery Disease and Coronary Disease, has completed, sponsored by Abbott Medical Devices.

COMPLETED
Registry status
5,034 participants
Enrollment target
1
Study location

Study Summary

XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. The objectives of this study are * To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and * To support the Food and Drug Administration (FDA) dual antiplatelet therapy (DAPT) initiative. This initiative is designed to evaluate the composite of all death, myocardial infarction (MI) and stroke (MACCE) and the survival of patients that are free from Academic Research Consortium (ARC) definite or probable stent thrombosis (ST) and that have been treated with drug eluting stents (DES) and extended dual antiplatelet therapy.

Conditions Studied

Coronary Artery Disease Coronary Disease Myocardial Ischemia Vascular Disease Coronary Artery Stenosis Coronary Restenosis Chronic Coronary Occlusion

Interventions

  • DEVICE XIENCE V® EECSS

Study Locations (1)

California

  • Abbott Vascular - Santa Clara

Trial Details

FieldValue
Enrollment Target 5,034 participants
Start Date 2008-07
Est. Completion 2013-12

Sponsor

Abbott Medical Devices

261 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01120379

The ClinicalTrials.gov registry entry for NCT01120379 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5,034 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,264-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (298% higher). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which XIENCE V® EECSS is the first listed.

NCT01120379 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01120379 about?

NCT01120379 is a clinical study titled "XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)". XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. The objectives of this study are * To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and * To support the Food and Drug Administration (FDA) dual antiplatelet the...

What is the current status of trial NCT01120379?

This trial is currently completed. The enrollment target is 5,034 participants. The study started on 2008-07. Estimated completion is 2013-12.

What conditions does trial NCT01120379 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Vascular Disease, Coronary Artery Stenosis.

What interventions are being tested in trial NCT01120379?

The interventions under investigation include: XIENCE V® EECSS (DEVICE).

Who is sponsoring clinical trial NCT01120379?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01120379 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Coronary Artery Disease

All registered trials for this condition

Coronary Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.